B-cell lymphomas, version 3.2019: Featured updates to the NCCN Guidelines Journal Article


Authors: Zelenetz, A. D.; Gordon, L. I.; Abramson, J. S.; Advani, R. H.; Bartlett, N. L.; Caimi, P. F.; Chang, J. E.; Chavez, J. C.; Christian, B.; Fayad, L. E.; Glenn, M. J.; Habermann, T. M.; Harris, N. L.; Hernandez-Ilizaliturri, F.; Kaminski, M. S.; Kelsey, C. R.; Khan, N.; Krivacic, S.; LaCasce, A. S.; Mehta, A.; Nademanee, A.; Rabinovitch, R.; Reddy, N.; Reid, E.; Roberts, K. B.; Smith, S. D.; Snyder, E. D.; Swinnen, L. J.; VoseA, J. M.; Dwyer, M. A.; Sundar, H.
Article Title: B-cell lymphomas, version 3.2019: Featured updates to the NCCN Guidelines
Abstract: Diffuse large B-cell lymphomas (DLBCLs) and follicular lymphoma (FL) are the most common subtypes of B-cell non-Hodgkin's lymphomas in adults. Histologic transformation of FL to DLBCL (TFL) occurs in approximately 15% of patients and is generally associated with a poor clinical outcome. Phosphatidylinositol 3-kinase (PI3K) inhibitors have shown promising results in the treatment of relapsed/refractory FL. CAR T-cell therapy (axicabtagene ciloleucel and tisagenlecleucel) has emerged as a novel treatment option for relapsed/refractory DLBCL and TFL. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines for B-Cell Lymphomas regarding the treatment of TFL and relapsed/refractory FL and DLBCL. © 2019 Harborside Press. All rights reserved.
Keywords: practice guideline; b cell lymphoma; follicular lymphoma; phosphatidylinositol 3 kinase inhibitor; phase 2 clinical trial (topic); multicenter study (topic); diffuse large b cell lymphoma; idelalisib; human; article; copanlisib; duvelisib; chimeric antigen receptor immunotherapy
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 17
Issue: 6
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2019-06-01
Start Page: 650
End Page: 661
Language: English
DOI: 10.6004/jnccn.2019.0029
PUBMED: 31200358
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 2 August 2019 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Andrew D Zelenetz
    604 Zelenetz